文献速递糖尿病肥胖与代谢综合征

每周一次IcoSema与每日多次胰岛素注射在2型糖尿病管理中的比较(COMBINE 3):一项开放标签、多中心、治疗达标、非劣效性、随机、3a期试验

Once-weekly IcoSema versus multiple daily insulin injections in type 2 diabetes management (COMBINE 3): an open-label, multicentre, treat-to-target, non-inferiority, randomised, phase 3a trial.
PubMed 文献 · Lancet Diabetes Endocrinol · 2025-06-04

COMBINE 3试验在14国109个门诊和医院科室纳入679例每日基础胰岛素控制不佳的2型糖尿病患者,随机接受每周一次IcoSema或基础-餐时胰岛素治疗52周。IcoSema在HbA1c降低上非劣于基础-餐时方案,并在体重变化、每周总胰岛素剂量和低血糖发生率上显示优效性。

要点

  • IcoSema组52周HbA1c降低1.47个百分点,基础-餐时组降低1.40个百分点,非劣效性成立。
  • IcoSema组体重变化优于基础-餐时组,估计治疗差异为-6.72 kg。
  • IcoSema组每周总胰岛素剂量和临床显著或严重低血糖发生率均低于基础-餐时组。

核心结论

  • 每周一次IcoSema在HbA1c降低上非劣于每日基础-餐时胰岛素治疗,并在体重变化、每周总胰岛素剂量和低血糖发生率上显示优效性。
  • 作者认为,对于成人2型糖尿病患者,IcoSema可能是一种潜在有益的治疗强化选择。

研究设计与样本

  • COMBINE 3是一项52周、开放标签、治疗达标、非劣效性、随机、3a期试验,在14个国家的109个门诊诊所和医院科室进行。
  • 纳入年龄18岁及以上、HbA1c 7.0-10.0%(53.0-85.8 mmol/mol)、每日接受基础胰岛素20-80 U的2型糖尿病患者,按1:1随机分配至每周一次IcoSema注射(n=340)或基础-餐时胰岛素治疗(每日一次甘精胰岛素U100联合每日二至四次门冬胰岛素,n=339)。
  • 主要终点为从基线至第52周HbA1c变化,非劣效性界值为0.3个百分点;确证性次要终点包括第52周体重变化、第50-52周每周总胰岛素剂量及基线至第57周临床显著或严重低血糖发作。
  • 主要和确证性次要终点采用全分析集(所有随机分配参与者)评估;安全性终点描述性统计基于安全性分析集(暴露于试验产品的参与者),统计分析基于全分析集。
  • 试验注册号ClinicalTrials.gov NCT05013229,已完成。

主要发现

  • 2021年11月30日至2022年9月28日筛查844人,随机分配679人(平均年龄59.6岁[SD 10.4];男性399人[59%],女性280人[41%])至IcoSema组(n=340)或基础-餐时组(n=339)。
  • 第52周HbA1c估计平均变化:IcoSema组-1.47个百分点(SE 0.05;-16.0 mmol/mol [0.6]),基础-餐时组-1.40个百分点(SE 0.06;-15.3 mmol/mol [0.7]),估计治疗差异-0.06个百分点(95% CI -0.22至0.09;-0.70 mmol/mol [-2.39至0.99];p<0.0001),证实非劣效性。
  • 第52周体重变化估计治疗差异为-6.72 kg(95% CI -7.58至-5.86;p<0.0001),IcoSema优于基础-餐时组。
  • 第50-52周每周总胰岛素剂量估计治疗差异为-270 U(95% CI -303至-236;p<0.0001),IcoSema优于基础-餐时组。
  • 基线至第57周临床显著或严重低血糖总发生率:IcoSema组0.21次/人年暴露 vs 基础-餐时组2.23次/人年暴露,估计率比0.12(95% CI 0.08至0.17;p<0.0001)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: IcoSema is a once-weekly combination therapy of basal insulin icodec (icodec) and semaglutide (a GLP-1 analogue) developed for the treatment of type 2 diabetes. We aimed to evaluate the efficacy and safety of IcoSema versus basal-bolus therapy (BBT) in adults with type 2 diabetes inadequately controlled on daily basal insulin. METHODS: COMBINE 3, a 52-week, open-label, treat-to-target, non-inferiority, randomised, phase 3a trial, was done across 109 outpatient clinics and hospital departments in 14 countries. Individuals aged 18 years or older with type 2 diabetes (HbA1c 7·0-10·0% [53·0-85·8 mmol/mol]) receiving daily basal insulin (20-80 U per day) were randomly assigned (1:1) to receive once-weekly IcoSema injection using a pen device or BBT (once-daily insulin glargine U100 with two to four daily insulin aspart injections) using an automated, interactive central web-response system. The primary endpoint was change in HbA1c from baseline to week 52, tested for non-inferiority (0·3 percentage-point margin). Confirmatory secondary endpoints were change in bodyweight from baseline to week 52; weekly total insulin dose during weeks 50-52; and combined clinically significant hypoglycaemic episodes (<3·0 mmol/L [<54 mg/dL], confirmed by blood glucose meter) or severe hypoglycaemic episodes (associated with severe cognitive impairment requiring external assistance for recovery) from baseline to week 57. The primary and confirmatory secondary endpoints were evaluated using the full analysis set (all randomly assigned participants). Descriptive statistics for safety endpoints were based on the safety analysis set (participants exposed to a trial product), with statistical analyses based on the full analysis set. This trial is registered with ClinicalTrials.gov (NCT05013229) and is complete. FINDINGS: Between Nov 30, 2021, and Sept 28, 2022, 844 participants were screened; 679 (mean age 59·6 years [SD 10·4]; 399 [59%] males and 280 [41%] females) were randomly assigned to IcoSema (n=340) or BBT (n=339). At week 52, estimated mean change in HbA1c was -1·47 percentage points (SE 0·05; -16·0 mmol/mol [0·6]) with IcoSema and -1·40 percentage points (0·06; -15·3 mmol/mol [0·7]) with BBT, confirming non-inferiority of IcoSema versus BBT (estimated treatment difference [ETD] -0·06 percentage points [95% CI -0·22 to 0·09; -0·70 mmol/mol [-2·39 to 0·99]; p<0·0001). Superiority was confirmed for IcoSema versus BBT for change in bodyweight from baseline to week 52 (ETD -6·72 kg [95% CI -7·58 to -5·86]; p<0·0001), weekly total insulin dose during weeks 50-52 (ETD -270 U [-303 to -236]; p<0·0001), and overall rate of clinically significant or severe hypoglycaemia from baseline to week 57 (0·21 vs 2·23 episodes per person-year of exposure; estimated rate ratio 0·12 [0·08 to 0·17]; p<0·0001). The most frequently reported adverse events during the trial were gastrointestinal disorders with IcoSema (148 [44%] of 340 participants had 443 events) and infections and infestations with BBT (116 [35%] of 328 participants had 193 events). INTERPRETATION: Once-weekly IcoSema achieved non-inferior HbA1c reduction and superiority in change in bodyweight, weekly total insulin dose, and hypoglycaemia rates versus daily BBT, suggesting that there is a potentially beneficial treatment intensification option for adults with type 2 diabetes. FUNDING: Novo Nordisk.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Billings LK, Andreozzi F, Frederiksen M, et al. Once-weekly IcoSema versus multiple daily insulin injections in type 2 diabetes management (COMBINE 3): an open-label, multicentre, treat-to-target, non-inferiority, randomised, phase 3a trial. Lancet Diabetes Endocrinol. 2025. PMID: 40482670. doi:10.1016/S2213-8587(25)00052-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。